12 Oversold Growth Stocks to Buy According to Analysts

Page 9 of 11

3. Telix Pharmaceuticals Limited (NASDAQ:TLX)

Year-to-Date Performance: -32.60%

Number of Hedge Fund Holders: 1

Analyst Upside Potential: 80.77%

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 23, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced that the US Centers for Medicare & Medicaid Services had granted Transitional Pass-Through payment status for Gozellix. Gozellix is the company’s next-generation PSMA-PET imaging agent for prostate cancer.

The Transitional Pass-Through payment status means that hospitals will get separate reimbursement for using Gozellix starting October 1, 2025. Gozellix is a kit used to prepare gallium-68 Gozetotide for PET scans that helps detect PSMA-positive lesions in men with prostate cancer, especially those suspected of metastasis or biochemical recurrence.

Moreover, it has also been assigned a permanent HCPCS Level II code A9616, allowing recognition by CMS and commercial insurers for reimbursement starting October 1, 2025.

Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals.

Page 9 of 11